Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Short Interest Down 84.4% in March

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the target of a significant drop in short interest in March. As of March 13th, there was short interest totaling 198,425 shares, a drop of 84.4% from the February 26th total of 1,274,209 shares. Based on an average daily trading volume, of 233,058 shares, the days-to-cover ratio is currently 0.9 days. Currently, 1.4% of the shares of the stock are sold short. Currently, 1.4% of the shares of the stock are sold short. Based on an average daily trading volume, of 233,058 shares, the days-to-cover ratio is currently 0.9 days.

Institutional Investors Weigh In On Kairos Pharma

Several hedge funds have recently modified their holdings of the company. FNY Investment Advisers LLC purchased a new stake in Kairos Pharma in the 3rd quarter worth approximately $27,000. XTX Topco Ltd boosted its position in shares of Kairos Pharma by 290.8% in the fourth quarter. XTX Topco Ltd now owns 48,494 shares of the company’s stock worth $34,000 after acquiring an additional 36,086 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in shares of Kairos Pharma in the third quarter worth approximately $54,000.

Kairos Pharma Stock Down 4.4%

Shares of Kairos Pharma stock traded down $0.03 on Wednesday, hitting $0.60. The company’s stock had a trading volume of 36,563 shares, compared to its average volume of 565,401. The company has a market capitalization of $12.53 million, a P/E ratio of -1.94 and a beta of 2.28. Kairos Pharma has a 52-week low of $0.40 and a 52-week high of $2.11. The firm has a fifty day moving average price of $0.66 and a 200-day moving average price of $0.89.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.